title: Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis.
abstract: The 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) model leads to chronic cholestatic liver injury and therefore resembles human diseases such as sclerosing cholangitis and forms of metabolic liver diseases. The role of the interleukin-6/glycoprotein 130 (gp130) system in this context is still undefined. Therefore, conditional gp130 knockout and knockin mice were used to achieve hepatocyte-specific deletions of gp130 (gp130(Deltahepa)), gp130-dependent ras (gp130(DeltahepaRas)), and signal transducer and activator of transcription (STAT) (gp130(DeltahepaSTAT)) activation. These mice were treated with a DDC-containing diet and analyzed over time. Mice deficient in hepatic gp130 and STAT signaling showed increased and earlier mortality than wild-type and gp130(DeltahepaRas) animals. Over time, significantly more apoptosis and cholestasis became evident in gp130(Deltahepa) and gp130(DeltahepaSTAT) mice. These mice also displayed increased tumor necrosis factor-alpha expression, a diminished acute-phase response (lack of STAT3 and serum amyloid A activation), and enhanced immune cell infiltration in the liver. These were associated with stronger periportal oval cell activation. In addition, DDC treatment in gp130(Deltahepa) and gp130(DeltahepaSTAT) mice resulted in significantly stronger hepatic stellate cell activation. Long-term analysis revealed the development of severe liver fibrosis in gp130(Deltahepa) and gp130(DeltahepaSTAT) animals, as evidenced by increased collagen accumulation. Here we demonstrate that gp130/STAT signaling in hepatocytes provides protection in a cholestatic hepatitis mouse model. STAT3-dependent signaling pathways in hepatocytes protect from apoptosis and tissue injury, which subsequently reduce oval cell activation and prevent fibrosis progression.
authors.affiliation: Department of Medicine III, University Hospital Aachen, Aachen, Germany.
authors.forename: Werner
authors.initials: W
authors.lastname: Plum
authors.forename: Darjus F
authors.initials: DF
authors.lastname: Tschaharganeh
authors.forename: Daniela C
authors.initials: DC
authors.lastname: Kroy
authors.forename: Eva
authors.initials: E
authors.lastname: Corsten
authors.forename: Stephanie
authors.initials: S
authors.lastname: Erschfeld
authors.forename: Uta
authors.initials: U
authors.lastname: Dierssen
authors.forename: Hermann
authors.initials: H
authors.lastname: Wasmuth
authors.forename: Christian
authors.initials: C
authors.lastname: Trautwein
authors.forename: Konrad L
authors.initials: KL
authors.lastname: Streetz
mesh_terms: D000483:Alleles; D000818:Animals; D017209:Apoptosis; D015209:Cholangitis, Sclerosing / Q000473:pathology*; D002779:Cholestasis / Q000473:pathology; D050822:Cytokine Receptor gp130 / Q000378:metabolism*; D018450:Disease Progression; D005355:Fibrosis / Q000378:metabolism*; D022781:Hepatocytes / Q000166:cytology*; D008099:Liver / Q000293:injuries* / Q000473:pathology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D050822:Cytokine Receptor gp130
references.citation: J Biol Chem. 2008 Apr 11;283(15):9886-95
references.pmid: 18216023
references.citation: Liver. 2000 Apr;20(2):114-24
references.pmid: 10847479
references.citation: J Biol Chem. 2009 Jan 30;284(5):2908-2916
references.pmid: 19017654
references.citation: J Biol Chem. 2001 Jul 13;276(28):26605-13
references.pmid: 11349125
references.citation: Hepatology. 2007 Jun;45(6):1462-70
references.pmid: 17538966
references.citation: Exp Cell Res. 2005 May 15;306(1):252-63
references.pmid: 15878349
references.citation: J Clin Invest. 2005 Apr;115(4):860-9
references.pmid: 15761498
references.citation: Hepatology. 2009 Jan;49(1):227-39
references.pmid: 19111021
references.citation: Hepatology. 2006 Nov;44(5):1206-17
references.pmid: 17058237
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9589-94
references.pmid: 15976028
references.citation: Hepatology. 2008 Apr;47(4):1317-30
references.pmid: 18220275
references.citation: J Immunol. 2008 Sep 1;181(5):3586-94
references.pmid: 18714032
references.citation: Hepatology. 2003 Jul;38(1):218-29
references.pmid: 12830005
references.citation: Nature. 1994 Mar 24;368(6469):339-42
references.pmid: 8127368
references.citation: Gastroenterology. 2003 Aug;125(2):532-43
references.pmid: 12891556
references.citation: Am J Pathol. 2005 Mar;166(3):709-19
references.pmid: 15743783
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11881-8
references.pmid: 12902545
references.citation: Am J Pathol. 2000 May;156(5):1627-39
references.pmid: 10793074
references.citation: Hepatology. 2007 Jan;45(1):31-41
references.pmid: 17187411
references.citation: PLoS One. 2008 Jun 18;3(6):e2493
references.pmid: 18560566
references.citation: Am J Pathol. 2007 Aug;171(2):525-36
references.pmid: 17600122
references.citation: Gastroenterology. 2003 Jul;125(1):202-15
references.pmid: 12851884
references.citation: Liver Int. 2005 Jun;25(3):633-46
references.pmid: 15910501
references.citation: J Exp Med. 1998 Nov 16;188(10):1955-65
references.pmid: 9815272
references.citation: Am J Pathol. 2007 Sep;171(3):872-81
references.pmid: 17640959
references.citation: Genesis. 2000 Feb;26(2):151-3
references.pmid: 10686615
references.citation: Histochem Cell Biol. 2008 Jun;129(6):735-49
references.pmid: 18443813
references.citation: J Exp Med. 2001 Jul 16;194(2):189-203
references.pmid: 11457894
references.citation: J Exp Med. 2000 Dec 18;192(12):1809-18
references.pmid: 11120777
references.citation: Hepatology. 2007 Feb;45(2):486-94
references.pmid: 17256754